Analgesics Market Size to Worth US$ 149.3 Billion by 2030

According to the new research report published by Precedence Research, titled “Analgesics Market (By Drug Class: Opioids, NSAIDs, Local Anesthetics, Acetaminophen; By Indication: Surgical Pain, Cancer Pain, Neuropathic Pain, Others; By Type: Prescription, OTC; By Pain Type; By Application; By Route of Administration; By Distribution Channel) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”, the global analgesics market size is expected to be worth around US$ 149.3 billion by 2030 and is poised to record a yearly growth rate of 3.9% from 2022 to 2030. The study investigates several elements and their consequences on the growth of the all-wheel drive market.

This report focuses on analgesics market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall analgesics market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.

 The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2282

The study also provides important advancements in organic and inorganic growth strategies in the worldwide analgesics market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of analgesics market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.

Analgesics Market  Report Scope 

Also read: https://www.uswebwire.com/dental-support-organizations-market-dental-support-organizations-market/

Market Key Players

Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the analgesics market.

Some of the prominent players in the analgesics market include are  Abbott, Pfizer Inc., Eli Lilly & Company, Endo International plc, F. Hoffmann-La Roche AG Bausch Health Companies Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Johnson & Johnson Private Limited, GSK plc., Purdue Pharma L.P.

Analgesics Market Segmentations 

By Drug Class

• Opioids
  • Morphine
  • Fentanyl
  • Codiene
  • Methadone
  • Meperidine
  • Oxycodone
  • Tramadol
  • Dextromethorphan
  • Buprenorphine
  • Others
• NSAIDs
• Local Anesthetics
• Acetaminophen

By Indication

• Surgical Pain
• Cancer Pain
• Neuropathic Pain
• Others

By Type

• Prescription
• OTC

By Pain Type

• Musculoskeletal Pain
• Surgical and Trauma Pain
• Cancer Pain
• Neuropathic Pain
• Migraine
• Obstetrical Pain
• Fibromyalgia
• Pain due to Burns
• Dental/Facial Pain
• Paediatric Pain
• Others

By Application

• Internal Analgesics
• External Analgesics

By Route of Administration

• Oral
• Parenteral
• Transdermal
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Drug Stores
• Online pharmacies

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Report Objectives 

• To define, segment, and project the global market size for analgesics market
• To understand the structure of the market by identifying its various sub-segments
• To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
• To analyze the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
• To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
• To profile key players and comprehensively analyze their core competencies
• To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
• To analyze the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements 

TABLE OF CONTENT

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Analgesics Market, By Drug Class

7.1. Analgesics Market, by Drug Class, 2022-2030

7.1.1. Opioids

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. NSAIDs

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Local Anesthetics

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Acetaminophen

7.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Analgesics Market, By Indication

8.1. Analgesics Market, by Indication, 2022-2030

8.1.1. Surgical Pain

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Cancer Pain

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Neuropathic Pain

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Analgesics Market, By Type

9.1. Analgesics Market, by Type, 2022-2030

9.1.1. Prescription

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. OTC

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Analgesics Market, By Pain Type

10.1. Analgesics Market, by Pain Type, 2022-2030

10.1.1. Musculoskeletal Pain

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Surgical and Trauma Pain

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Cancer Pain

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Neuropathic Pain

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Migraine

10.1.5.1. Market Revenue and Forecast (2017-2030)

10.1.6. Obstetrical Pain

10.1.6.1. Market Revenue and Forecast (2017-2030)

10.1.7. Fibromyalgia

10.1.7.1. Market Revenue and Forecast (2017-2030)

10.1.8. Pain due to Burns

10.1.8.1. Market Revenue and Forecast (2017-2030)

10.1.9. Dental/Facial Pain

10.1.9.1. Market Revenue and Forecast (2017-2030)

10.1.10. Paediatric Pain

10.1.10.1. Market Revenue and Forecast (2017-2030)

10.1.11. Others

10.1.11.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Analgesics Market, By Application

11.1. Analgesics Market, by Application, 2022-2030

11.1.1. Internal Analgesics

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. External Analgesics

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Analgesics Market, By Route of Administration

12.1. Analgesics Market, by Route of Administration, 2022-2030

12.1.1. Oral

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Oral

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Transdermal

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Others

12.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Analgesics Market, By Distribution Channel

13.1. Analgesics Market, by Distribution Channel, 2022-2030

13.1.1. Hospital pharmacies

13.1.1.1. Market Revenue and Forecast (2017-2030)

13.1.2. Retail pharmacies

13.1.2.1. Market Revenue and Forecast (2017-2030)

13.1.3. Drug Stores

13.1.3.1. Market Revenue and Forecast (2017-2030)

13.1.4. Online pharmacies

13.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 14. Global Analgesics Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.8. U.S.

14.1.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.1.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.1.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.1.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.1.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.1.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.1.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2. Europe

14.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.8. UK

14.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.9. Germany

14.2.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.10. France

14.2.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.2.11. Rest of Europe

14.2.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.2.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.2.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.2.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.2.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.2.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.2.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3. APAC

14.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.8. India

14.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.9. China

14.3.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.10. Japan

14.3.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.3.11. Rest of APAC

14.3.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.3.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.3.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.3.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.3.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.3.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.3.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4. MEA

14.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.8. GCC

14.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.9. North Africa

14.4.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.10. South Africa

14.4.10.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.10.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.10.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.10.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.10.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.10.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.10.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.4.11. Rest of MEA

14.4.11.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.4.11.2. Market Revenue and Forecast, by Indication (2017-2030)

14.4.11.3. Market Revenue and Forecast, by Type (2017-2030)

14.4.11.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.4.11.5. Market Revenue and Forecast, by Application (2017-2030)

14.4.11.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.4.11.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5. Latin America

14.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.8. Brazil

14.5.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.8.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.8.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.8.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.8.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.8.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.8.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Forecast, by Drug Class (2017-2030)

14.5.9.2. Market Revenue and Forecast, by Indication (2017-2030)

14.5.9.3. Market Revenue and Forecast, by Type (2017-2030)

14.5.9.4. Market Revenue and Forecast, by Pain Type (2017-2030)

14.5.9.5. Market Revenue and Forecast, by Application (2017-2030)

14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2017-2030)

14.5.9.7. Market Revenue and Forecast, by Route of Administration (2017-2030)

Chapter 15. Company Profiles

15.1. Abbott

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Pfizer Inc.

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Eli Lilly & Company

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Endo International plc

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. F. Hoffmann-La Roche AG

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. Bausch Health Companies Inc.

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Merck & Co. Inc.

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. AbbVie Inc.

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Novartis AG

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. Johnson & Johnson Private Limited

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

Why should you invest in this report?

If you are aiming to enter the global analgesics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for analgesics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

 

---